Cycling Fat-Loss Peptides: Reported Schedules and Evidence

Fat-loss peptides and the evidence behind them

Fat loss peptide cycling guides aim to maximize lipolysis while minimizing side effects and maintaining muscle mass. The tables pair the mechanisms they claim with the best human evidence we found as of October 2026.

Compounds guides list for fat loss

Other compounds in fat-loss stacks

AOD-9604 (hGH 177-191 plus a tyrosine) is the hGH fragment that actually went through human trials. In the largest, the OPTIONS trial, 502 adults with obesity took oral doses of 0.25, 0.5 or 1 mg a day. Weight loss at 12 weeks wasn't significantly different from placebo, and the sponsor ended development for obesity in 2007, according to FDA's 2024 advisory committee briefing.

The medicines with large human fat-loss data are prescription GLP-1 drugs. In adults with obesity, semaglutide 2.4 mg weekly produced 14.9% average weight loss at 68 weeks in the STEP 1 trial, and tirzepatide 15 mg weekly about 20.9% at 72 weeks in SURMOUNT-1. Research-use vials sold under these names aren't the approved medicines; our comparison of peptides by evidence strength covers the gap.

Why people cycle these peptides

The usual reason given is that the body responds less after weeks of steady use. The best human data come from another GH-releasing peptide. In a 1998 study, 12 healthy older adults injected hexarelin twice daily for 16 weeks. Their GH response fell by about 45%, then returned to baseline when hexarelin was given again 4 weeks after the course ended. Nobody has run a similar study for ipamorelin, CJC-1295, tesamorelin or the fragments. The 4-6 week off-cycle that forum guides say will allow receptor reset fits that one study loosely, but it's a convention, not a tested schedule.

Reported cycle lengths by compound

Fragment 176-191

Forum and vendor guides describe twice-daily injections in fasted states, morning and before bed. We couldn't trace their doses or durations to any study, so we don't repeat them.

AOD-9604

Forum users most often describe 300 mcg by subcutaneous injection once daily, fasted in the morning, for about 12 weeks, with reports running 300-500 mcg a day. No human trial has tested injected AOD-9604, and users mostly report noticing little.

GH secretagogues and tesamorelin

Users most often describe Mod GRF 1-29 (CJC-1295 without DAC) and ipamorelin at 100-300 mcg each at bedtime, often 5 days on and 2 off. Vendor guidance lists ipamorelin at 200-300 mcg two or three times a day for 8-12 weeks. The loading and taper phases in many guides have no trial behind them.

Tesamorelin is FDA-approved only to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and its label says it isn't indicated for weight-loss management. Label doses are once-daily subcutaneous injections of 2 mg (original Egrifta), 1.4 mg (Egrifta SV) or 1.28 mg (Egrifta WR, approved March 2025), and the formulations aren't interchangeable mg for mg. Users outside that population commonly report 1-2 mg nightly, often 5 days on and 2 off.

MOTS-c

The most common forum pattern is 5 mg two or three times a week (10-15 mg weekly) by subcutaneous injection for 4-8 weeks. Some guides list an "aggressive" 10-15 mg three times weekly (30-45 mg a week), far above those reports. No human dose-finding study exists for native MOTS-c. The analog CB4211 was tested at 25 mg daily for 4 weeks in a small Phase 1 trial, but it's a different molecule and its development has stopped.

Combinations described in forum guides

Stack guides typically pair Fragment 176-191, fasted AM and before bed, with CJC-1295 (no DAC) pre-bed with a GHRP such as ipamorelin. Recomposition versions swap the fragment for MOTS-c and add BPC-157 for recovery support. No controlled trial has tested these combinations. For the mitochondrial angle, see mitochondrial peptides in fat-loss phases.

Timing claims and insulin

Users time GH secretagogues before bed to match the overnight GH pulse. Guides also describe injecting Fragment fasted, on the reasoning that insulin blocks lipolysis, and describe a wait of 30-60 min before eating after Fragment to allow fat mobilization. They treat GH secretagogues as also best fasted, since insulin blunts GH release, and favor low-carb meals around dosing to minimize insulin response. No study has tested whether meal timing changes results with these peptides, and the tesamorelin labels set no time of day or fasting rule.

Maintaining Results Off-Cycle

In the tesamorelin trials, people switched to placebo after 26 weeks saw visceral fat rise again by about 16-22% over the next 26 weeks, while it held steady in those who stayed on the drug. Forum guides focus on habits rather than peptides off-cycle:

For stalls, the same guides suggest:

None of these has been tested alongside peptide cycles.

Monitoring During Fat Loss Cycles

The tesamorelin label advises checking glucose before and during treatment and monitoring IGF-1, because some trial participants developed higher blood sugar and IGF-1 above the normal range. Forum guides add blood work mid-phase and a final check of photos and measurements alongside blood work.

Weekly Tracking

Blood work users commonly describe

This schedule is community practice, not a tested protocol; our monitoring protocols page explains what each marker can show. WADA's 2026 Prohibited List names hGH 176-191 and MOTS-c, and bans GH secretagogues such as ipamorelin; see peptides and sports rules.

What we still don't know

We found no human evidence that Fragment 176-191 reduces body fat. Whether GH secretagogues lose effect the way hexarelin did, and how long a break restores the response, hasn't been studied. MOTS-c has no published human administration data, and the only listed Phase 2 trial comes from a sponsor whose registry records are disputed.